Muscarinic receptors in the human brain: In health and in sickness
Grant number: 1045619 | Funding period: 2013 - 2015
Schizophrenia is a severe mental illness, with sub-optimal treatment outcomes. New drugs are being designed to provide more effective treatment. To understand the effects of these drugs, we need to know which brain cells have the protein these new drugs target and which cells are affected in schizophrenia. Our project will determine the localisation of this drug target; this knowledge will help the development of better treatments for schizophrenia.
Related publications (11)
Muscarinic receptor binding changes in postmortem Parkinson's disease
Caitlin McOmish, Geoff Pavey, Catriona McLean, Malcolm Horne, Brian Dean, Elizabeth Scarr
Parkinson's disease (PD) is a devastating disorder, affecting approximately 2% of people aged 60 and above. It is marked by progre..
The distribution of muscarinic M1 receptors in the human hippocampus
Elizabeth Scarr, Myoung Suk Seo, Timothy Douglas Aumann, Gursharan Chana, Ian Paul Everall, Brian Dean
The muscarinic M1 receptor plays a significant role in cognition, probably by modulating information processing in key regions suc..
Validating reference genes using minimally transformed qpcr data: findings in human cortex and outcomes in schizophrenia
Brian Dean, Madhara Udawela, Elizabeth Scarr
BACKGROUND: It is common practice, when using quantitative real time polymerase chain reaction (qPCR), to normalise levels of mRNA..
Changes in BQCA Allosteric Modulation of [H-3]NMS Binding to Human Cortex within Schizophrenia and by Divalent Cations
Brian Dean, Shaun Hopper, P Jeffrey Conn, Elizabeth Scarr
Stimulation of the cortical muscarinic M1 receptor (CHRM1) is proposed as a treatment for schizophrenia, a hypothesis testable usi..
Lower [3H]LY341495 binding to mGlu2/3 receptors in the anterior cingulate of subjects with major depressive disorder but not bipolar disorder or schizophrenia
Caitlin E McOmish, Geoff Pavey, Andrew Gibbons, Shaun Hopper, Madhara Udawela, Elizabeth Scarr, Brian Dean
INTRODUCTION: The glutamatergic system has recently been implicated in the pathogenesis and treatment of major depressive disorder..
Changes in cholinergic and glutamatergic markers in the striatum from a sub-set of subjects with schizophrenia
Brian Dean, Natalie Thomas, Chi-Yu Lai, Wei J Chen, Elizabeth Scarr
BACKGROUND/OBJECTIVES: Having separated a sub-group of people with schizophrenia based on a marked loss of cortical [(3)H]pirenzep..
The Role of Muscarinic Receptors in the Pathophysiology of Mood Disorders: A Potential Novel Treatment?
Won Je Jeon, Brian Dean, Elizabeth Scarr, Andrew Gibbons
The central cholinergic system has been implicated in the pathophysiology of mood disorders. An imbalance in central cholinergic n..